Mr. Donghoon Lee is the Chief Executive Officer and President of SK Biopharmaceuticals and its U.S. subsidiaries SK Life Science, Inc. and SK Life Science Labs. His vision is to transform all three companies so that together they become a global biotech leader while generating synergy with SK Group, its affiliates, and partners.
Previously, Mr. Lee was the Executive Vice President and Head of Bio Investment Center of SK Inc. where he executed key investment deals in line with SK Group’s vision to fortify a variety of business units as its main growth drivers.
He spearheaded SK’s global deals such as launching a U.S. joint venture called ProteoVant—which is now SK Life Science Labs—with Switzerland-based Roivant Sciences; acquiring France-based Yposkesi, a CDMO for cell and gene therapies; and making investments in the Center for Breakthrough Medicines.
Mr. Lee previously held leadership positions at the global professional services firm, KPMG, and pharmaceutical companies, including as the CEO and Executive Vice President of Dong-A Socio Holdings. Mr. Lee was educated at Seoul National University and at Ohio State University where he received his MBA in Finance and Accounting.